188 related articles for article (PubMed ID: 35957836)
1. Addition of Capecitabine to Adjuvant Chemotherapy May be the Most Effective Strategy for Patients With Early-Stage Triple-Negative Breast Cancer: A Network Meta-Analysis of 9 Randomized Controlled Trials.
Li Z; Zheng J; Ji Z; Chen L; Wu J; Zou J; Liu Y; Lin W; Cai J; Chen Y; Chen Y; Lu H
Front Endocrinol (Lausanne); 2022; 13():939048. PubMed ID: 35957836
[TBL] [Abstract][Full Text] [Related]
2. The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis.
Huo X; Li J; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
BMC Cancer; 2021 Jan; 21(1):78. PubMed ID: 33468087
[TBL] [Abstract][Full Text] [Related]
3. Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials.
Natori A; Ethier JL; Amir E; Cescon DW
Eur J Cancer; 2017 May; 77():40-47. PubMed ID: 28355581
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant addition of capecitabine to early-stage triple-negative breast cancer patients receiving standard chemotherapy: a meta-analysis.
Li Y; Zhou Y; Mao F; Lin Y; Zhang X; Shen S; Sun Q
Breast Cancer Res Treat; 2020 Feb; 179(3):533-542. PubMed ID: 31865475
[TBL] [Abstract][Full Text] [Related]
5. Role and efficacy of capecitabine in the anthracycline-free regimen in breast cancer patients: a systematic review and meta-analysis.
Wang S; Deng L; Chen J; Li Y; Zhong Y; Wang Y; Cao H
J Cancer Res Clin Oncol; 2023 Dec; 149(19):17671-17682. PubMed ID: 37891407
[TBL] [Abstract][Full Text] [Related]
6. Additional capecitabine use in early-stage triple negative breast cancer patients receiving standard chemotherapy: a new era? A meta-analysis of randomized controlled trials.
Ye F; Bian L; Wen J; Yu P; Li N; Xie X; Wang X
BMC Cancer; 2022 Mar; 22(1):261. PubMed ID: 35279130
[TBL] [Abstract][Full Text] [Related]
7. Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients.
van Mackelenbergh MT; Seither F; Möbus V; O'Shaughnessy J; Martin M; Joensuu H; Untch M; Nitz U; Steger GG; Miralles JJ; Barrios CH; Toi M; Bear HD; Muss H; Reimer T; Nekljudova V; Loibl S
Eur J Cancer; 2022 May; 166():185-201. PubMed ID: 35305453
[TBL] [Abstract][Full Text] [Related]
8. Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial.
Wang X; Wang SS; Huang H; Cai L; Zhao L; Peng RJ; Lin Y; Tang J; Zeng J; Zhang LH; Ke YL; Wang XM; Liu XM; Chen QJ; Zhang AQ; Xu F; Bi XW; Huang JJ; Li JB; Pang DM; Xue C; Shi YX; He ZY; Lin HX; An X; Xia W; Cao Y; Guo Y; Su YH; Hua X; Wang XY; Hong RX; Jiang KK; Song CG; Huang ZZ; Shi W; Zhong YY; Yuan ZY;
JAMA; 2021 Jan; 325(1):50-58. PubMed ID: 33300950
[TBL] [Abstract][Full Text] [Related]
9. Additional adjuvant capecitabine in early breast cancer patients: a meta-analysis of randomized controlled trials.
Zhou W; Cao Y; Gou P; Zeng X; Hu X; Lin Z; Ye C; Chen L; Yao G
Future Oncol; 2021 Dec; 17(35):4993-5002. PubMed ID: 34689590
[TBL] [Abstract][Full Text] [Related]
10. Capecitabine in Combination with Standard (Neo)Adjuvant Regimens in Early Breast Cancer: Survival Outcome from a Meta-Analysis of Randomized Controlled Trials.
Zhang ZC; Xu QN; Lin SL; Li XY
PLoS One; 2016; 11(10):e0164663. PubMed ID: 27741288
[TBL] [Abstract][Full Text] [Related]
11. Different Chemotherapy Regimens and Pathologic Complete Response in Triple-Negative Breast Cancer: An Updated Network Meta-Analysis of Phase 3 Trials.
Petrelli F; Tomasello G; Parati MC; Ghidini A; Ghidini M; Borgonovo K; Cabiddu M; Ghilardi M; Reduzzi R; Gambini D; Zaniboni A; Faustinelli G; Garrone O
Medicina (Kaunas); 2024 Feb; 60(2):. PubMed ID: 38399628
[No Abstract] [Full Text] [Related]
12. Adjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysis.
Petrelli F; Bertaglia V; Parati MC; Borgonovo K; De Silva P; Luciani A; Novello S; Scartozzi M; Emens LA; Solinas C
Breast; 2023 Feb; 67():8-13. PubMed ID: 36549170
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
Masuda N; Lee SJ; Ohtani S; Im YH; Lee ES; Yokota I; Kuroi K; Im SA; Park BW; Kim SB; Yanagita Y; Ohno S; Takao S; Aogi K; Iwata H; Jeong J; Kim A; Park KH; Sasano H; Ohashi Y; Toi M
N Engl J Med; 2017 Jun; 376(22):2147-2159. PubMed ID: 28564564
[TBL] [Abstract][Full Text] [Related]
14. The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer-A Meta-Analysis.
Zhang Z; Ma K; Li J; Guan Y; Yang C; Yan A; Zhu H
Front Pharmacol; 2021; 12():771839. PubMed ID: 34867401
[No Abstract] [Full Text] [Related]
15. Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients.
de Boo LW; Jóźwiak K; Joensuu H; Lindman H; Lauttia S; Opdam M; van Steenis C; Brugman W; Kluin RJC; Schouten PC; Kok M; Nederlof PM; Hauptmann M; Linn SC
Br J Cancer; 2022 Jun; 126(10):1401-1409. PubMed ID: 35124703
[TBL] [Abstract][Full Text] [Related]
16. Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01).
Lluch A; Barrios CH; Torrecillas L; Ruiz-Borrego M; Bines J; Segalla J; Guerrero-Zotano Á; García-Sáenz JA; Torres R; de la Haba J; García-Martínez E; Gómez HL; Llombart A; Bofill JS; Baena-Cañada JM; Barnadas A; Calvo L; Pérez-Michel L; Ramos M; Fernández I; Rodríguez-Lescure Á; Cárdenas J; Vinholes J; Martínez de Dueñas E; Godes MJ; Seguí MA; Antón A; López-Álvarez P; Moncayo J; Amorim G; Villar E; Reyes S; Sampaio C; Cardemil B; Escudero MJ; Bezares S; Carrasco E; Martín M; ; ;
J Clin Oncol; 2020 Jan; 38(3):203-213. PubMed ID: 31804894
[TBL] [Abstract][Full Text] [Related]
17. Capecitabine-based chemotherapy in early-stage triple-negative breast cancer: a meta-analysis.
Bai J; Yao X; Pu Y; Wang X; Luo X
Front Oncol; 2023; 13():1245650. PubMed ID: 37954087
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Capecitabine for Triple-Negative Breast Cancer: A Meta-Analysis.
Xun X; Cao Q; Hong P; Rai S; Zhou Y; Liu R; Hu H
Front Oncol; 2022; 12():899423. PubMed ID: 35875141
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant capecitabine for early triple-negative breast cancer: A meta-analysis of randomized controlled trials.
Liu M; Fang H; Qian S
Asian J Surg; 2022 Sep; 45(9):1748-1750. PubMed ID: 35168861
[No Abstract] [Full Text] [Related]
20. Comparison of S-1-based vs. capecitabine-based adjuvant chemotherapy for patients with gastric cancer: a systematic review and meta-analysis.
Zhang Q; Qian Y; Yin Y
Eur J Clin Pharmacol; 2021 Dec; 77(12):1791-1804. PubMed ID: 34275019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
